Trials / Completed
CompletedNCT00233545
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- AB Foundation · Academic / Other
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony. Standard dose regimens will be used for both drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | miltefosine | |
| DRUG | antimony |
Timeline
- Start date
- 2005-09-01
- Completion
- 2007-09-01
- First posted
- 2005-10-06
- Last updated
- 2010-06-02
Locations
1 site across 1 country: Bolivia
Source: ClinicalTrials.gov record NCT00233545. Inclusion in this directory is not an endorsement.